High expression and frequently humoral immune response of melanoma-associated antigen D4 in glioma

• Published in: International journal of clinical and experimental pathology Vol. 7; no. 5; pp. 2350 - 2360
• Main Authors: He, Shu-Jia, Gu, Yong-Yao, Yu, Liang, Luo, Bin, Fan, Rong, Lin, Wen-Zhen, Lan, Xiu-Wan, Lin, Yong-Da, Zhang, Qing-Mei, Xiao, Shao-Wen, Xie, Xiao-Xun
• Format: Journal Article
• Language: English
• Published: United States e-Century Publishing Corporation 01.01.2014
• Subjects: Adolescent; Adult; Antigens, Neoplasm - analysis; Antigens, Neoplasm - genetics; Antigens, Neoplasm - immunology; Biomarkers, Tumor - analysis; Biomarkers, Tumor - genetics; Biomarkers, Tumor - immunology; Biopsy; Brain Neoplasms - blood; Brain Neoplasms - genetics; Brain Neoplasms - immunology; Brain Neoplasms - pathology; Case-Control Studies; Child; Child, Preschool; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Glioma - blood; Glioma - genetics; Glioma - immunology; Glioma - pathology; Humans; Immunity, Humoral; Immunoglobulin G - blood; Immunohistochemistry; Male; Middle Aged; Neoplasm Proteins - analysis; Neoplasm Proteins - genetics; Neoplasm Proteins - immunology; Original; Real-Time Polymerase Chain Reaction; RNA, Messenger - analysis; Up-Regulation; Young Adult; tumor antigen; melanoma-associated antigen D4; Glioma; gene expression; immunogenicity
• ISSN: 1936-2625; 1936-2625

MAGE-D4 is a novel member of MAGE super-family. It has preliminarily been demonstrated that MAGE-D4 mRNA is not expressed in majority of normal tissues except for brain and ovary in which only trace amount of MAGE-D4 mRNA can be detected, but predominantly expressed in glioma. MAGE-D4 protein expression and its immunogenicity in glioma have not been elucidated well. This study was designed to analyze MAGE-D4 expression both at mRNA and protein level, characteristic of humoral immune response, and their relationships with glioma patients' clinicopathological parameters. Recombinant MAGE-D4 protein and antiserum were generated. Quantitative RT-PCR analysis revealed that MAGE-D4 mRNA expression was overall up-regulated in 41 glioma specimens compared with that in 14 normal brain tissues. Immunohistochemistry analysis showed that 78% (21/27) glioma tissues expressed MAGE-D4 protein, which was predominantly located in the cytoplasm of tumor cells, but absent in any neuroglia cell of normal brain tissues. ELISA analysis demonstrated that humoral response against MAGE-D4 was detected in 17% (7/41) of glioma patients' sera but not in 77 healthy donors. No apparent correlation was observed between the expression and immunogenicity of MAGE-D4 with clinicopathological parameters of glioma. In summary, these results indicate that MAGE-D4 is highly expressed in glioma and can develop specifically humoral response in glioma patients, which supports that it may be a promising biomarker for glioma diagnosis and immunotherapy.